Search
Chikungunya vaccine (live, attenuated)
go.drugbank.com/drugs/DB18701ApprovedInvestigationalChikungunya virus (CHIKV) is a member of the Alphavirus genus that was first identified in Tanzania in 1952.[A262051] It is spread primarily by the bite of infected mosquitos of the _Aedes_ genus. … [L48726] It is approved for use in patients 18 years of age and older who are at high-risk of exposure to chikungunya virus.
MN-246
go.drugbank.com/drugs/DB05981ExperimentalMN-246 is a novel ß3-adrenergic receptor agonist developed for the treatment of urinary incontinence by MediciNova Inc.
Veglin
go.drugbank.com/drugs/DB05890ExperimentalVEGF-AS (Veglin) is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by VasGene Therapeutics, Inc. for the treatment of a variety of malignancies including mesothelioma … Veglin is one of several newly developed non-chemotherapy drugs being tested for possible utilization in the ongoing struggle to combat malignant mesothelioma.
Dacomitinib
go.drugbank.com/drugs/DB11963ApprovedInvestigational[L4810] Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model[A39624], although further investigations are needed. … Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic IndexRaseglurant
go.drugbank.com/drugs/DB05070InvestigationalThe orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for the treatment of GERD, migraine and anxiety. … ADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM).
Teduglutide
go.drugbank.com/drugs/DB08900ApprovedInvestigationalFDA approved on December 21, 2012. … Teduglutide is a glucagon-like peptide-2 (GLP-2) analogue. It is made up of 33 amino acids and is manufactured using a strain of Escherichia coli modified by recombinant DNA technology.
Categories: Compounds used in a research, industrial, or household settingPozelimab
go.drugbank.com/drugs/DB15218ApprovedInvestigationalCD55-deficient protein-losing enteropathy (PLE), or CHAPLE disease, is an ultra-rare hereditary disease, with fewer than 100 patients diagnosed worldwide or fewer than 10 patients in the US. … [L47850] In August 18, 2023, pozelimab was approved by the FDA for the treatment of CHAPLE disease. It is currently the only treatment explicitly indicated for CHAPLE disease.[L47875]
Pyridostigmine
go.drugbank.com/drugs/DB00545ApprovedInvestigational[A231009, A231014, L32413, L32418] Pyridostigmine was granted initial FDA approval on April 6, 1955, as an oral tablet. … Myasthenia gravis is an autoimmune disease involving dysfunction at the neuromuscular junction, most commonly due to autoantibodies directed against the acetylcholine receptor (AChR), which results in
International brands: Kalymin NCapsicum
go.drugbank.com/drugs/DB10897ApprovedCapsicum (Chili pepper) allergenic extract is used in allergenic testing.
Mixtures: C Ottways Lax Tab, Salonpas pain relieving HOT-LBrentuximab vedotin
go.drugbank.com/drugs/DB08870ApprovedInvestigationalImportantly, bleomycin - a highly toxic agent - was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease.[L1739] … Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexProducts: ADCETRIS 50 MG (POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION), POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/VIAL